TCGA-OR-A5J8-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.609
- IL6_JAK_STAT3_SIGNALING+0.601
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.575
- INFLAMMATORY_RESPONSE+0.564
- INTERFERON_GAMMA_RESPONSE+0.536
- TNFA_SIGNALING_VIA_NFKB+0.520
- INTERFERON_ALPHA_RESPONSE+0.486
- IL2_STAT5_SIGNALING+0.463
- COAGULATION+0.425
- COMPLEMENT+0.407
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.574
- FATTY_ACID_METABOLISM-0.402
- PEROXISOME-0.373
- ADIPOGENESIS-0.302
- BILE_ACID_METABOLISM-0.279
- CHOLESTEROL_HOMEOSTASIS-0.269
- PROTEIN_SECRETION-0.213
- ESTROGEN_RESPONSE_LATE-0.167
- MYC_TARGETS_V2-0.127
- ESTROGEN_RESPONSE_EARLY-0.093
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BT-A3PK-01A-21R-A220-07 | — | — | 0.904 |
| 2 | TCGA-56-8503-01A-11R-2403-07 | — | cohortSQ1 | 0.897 |
| 3 | BS_3J85TTZM | MPNST | — | 0.893 |
| 4 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.887 |
| 5 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.878 |
| 6 | SRR650191 | — | — | 0.874 |
| 7 | SRR4296078 | — | cohortSQ1 | 0.872 |
| 8 | SRR4296104 | — | cohortA1 | 0.870 |
| 9 | s_150203_5b | EPN | Posterior Fossa EPN | 0.869 |
| 10 | R317 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.609 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.601 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.575 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.564 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.536 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.486 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.463 | Idelalisib | — uncovered |
| COAGULATION | 0.425 | Binimetinib | — uncovered |
| COMPLEMENT | 0.407 | Inavolisib | — uncovered |
| APOPTOSIS | 0.392 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.344 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.333 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.307 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.295 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.287 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.267 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.262 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.262 | Temsirolimus | — uncovered |